Sema Domain, Immunoglobulin Domain (Ig), Short Basic Domain, Secreted, (Semaphorin) 3E Proteine (SEMA3E)

Human Sema Domain, Immunoglobulin Domain (Ig), Short Basic Domain, Secreted, (Semaphorin) 3E (SEMA3E) Interaktionspartner

1. Sema3E induced cell proliferation via acting through the MAPK/ERK pathway.

2. Sema3E could be considered an essential regulatory mediator involved in modulation of neutrophil migration throughout the course of neutrophilic inflammation.

3. Results show high expression level of SEMA3E which correlated with lymph node involvement, metastatic progression and a significant association with poor prognosis in gastric cancer patients. Also, in vitro studies reveal that SEMA3E caused cell proliferation and anchorage-independent cell growth in the intestinal type of gastric cancer.

4. suggested that miR-4282 is a tumor suppressor in colorectal carcinoma cells and exerted its inhibitory effect on the tumor cells through targeting Sema3E by inhibiting Sema3E translation or enhancing Sema3E mRNA degradation

5. This study aims to investigate whether the Tribbles 3 Q84R polymorphism has profound effects on serum semaphorin 3E and what effect semaphorin 3E exerts on carotid atherosclerosis.

6. This study suggests that NRP1 expression and LVD are independent factors that are likely to predict the risk of LN metastasis in squamous cell carcinoma (SCC)of the tongue, whereas the expression of VEGFC, VEGFR3, CCR7, and SEMA3E are nonindependent predictive factors

7. Authors suggest that silencing of Sema3E contributes to the pathogenesis of gastric cancer.

8. Findings suggest that Plexin-D1/class III semaphorin (Sema3E) axis is triggered in systemic sclerosis (SSc) endothelium.

9. Infantile hemangioma-derived stem cells and endothelial cells are inhibited by SEMA3E and SEMA3F.

10. these results identify SEMA3E as an essential gene for GnRH neuron development, uncover a neurotrophic function for SEMA3E in the developing brain

11. The ANGPTL4 may be a candidate target in DME treatment and a biomarker of ischemic-induced retinopathy, including diabetic retinopathy.

12. Semaphorin 3d requires neuropilin 1 or PI3K/Akt, whereas semaphorin 3e requires plexin D1 in directing endothelial motility.

13. The identification and characterization of SH3BP1 as a novel downstream effector of Sema3E-PlexinD1 provides an explanation for how extracellular signals are translated into cytoskeletal changes and unique cell behavior.

14. Semaphorin 3E inhibits human airway smooth muscle cell proliferation and migration.

15. A critical role of Sema3E/Plexin D1 interaction in tumor resistance to apoptosis.

16. Loss of Sema3E expression is associated with biochemical recurrence of patients with low- and intermediate-risk prostate cancer.

17. Furin-resistant Sema3E inhibits endothelial cells and hampers tumour angiogenesis and tumour growth.

18. analysis of Sema3E/plexin-D1 mediated epithelial-to-mesenchymal transition in ovarian endometrioid cancer

19. a novel phospholipid-regulated antiangiogenic signaling pathway whereby Sema3E activates Arf6 through Plexin-D1 and consequently controls integrin-mediated endothelial cell attachment to the extracellular matrix and migration.

20. SEMA3E is a target gene of the BACH1 transcription factor according to ChIP-seq analysis in HEK 293 cells.